EPIX
Price
$1.86
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
27 days until earnings call
LXRX
Price
$1.19
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
119 days until earnings call
Ad is loading...

EPIX vs LXRX

Header iconEPIX vs LXRX Comparison
Open Charts EPIX vs LXRXBanner chart's image
ESSA Pharma
Price$1.86
Change-$0.00 (-0.00%)
Volume$535.73K
CapitalizationN/A
Lexicon Pharmaceuticals
Price$1.19
Change-$0.00 (-0.00%)
Volume$3.38M
CapitalizationN/A
EPIX vs LXRX Comparison Chart
Loading...
EPIX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
EPIX vs. LXRX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EPIX is a Sell and LXRX is a Buy.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (EPIX: $1.87 vs. LXRX: $1.19)
Brand notoriety: EPIX and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EPIX: 51% vs. LXRX: 97%
Market capitalization -- EPIX: $79.46M vs. LXRX: $390.41M
EPIX [@Biotechnology] is valued at $79.46M. LXRX’s [@Biotechnology] market capitalization is $390.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EPIX’s FA Score shows that 1 FA rating(s) are green whileLXRX’s FA Score has 0 green FA rating(s).

  • EPIX’s FA Score: 1 green, 4 red.
  • LXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, LXRX is a better buy in the long-term than EPIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EPIX’s TA Score shows that 4 TA indicator(s) are bullish while LXRX’s TA Score has 4 bullish TA indicator(s).

  • EPIX’s TA Score: 4 bullish, 5 bearish.
  • LXRX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than EPIX.

Price Growth

EPIX (@Biotechnology) experienced а +10.00% price change this week, while LXRX (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.86%. For the same industry, the average monthly price growth was +5.66%, and the average quarterly price growth was +6.44%.

Reported Earning Dates

EPIX is expected to report earnings on Feb 06, 2025.

LXRX is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-1.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($390M) has a higher market cap than EPIX($79.5M). LXRX YTD gains are higher at: -22.222 vs. EPIX (-71.667). EPIX has higher annual earnings (EBITDA): -27.57M vs. LXRX (-185.05M). LXRX has more cash in the bank: 310M vs. EPIX (131M). EPIX has less debt than LXRX: EPIX (342K) vs LXRX (101M). LXRX has higher revenues than EPIX: LXRX (3.64M) vs EPIX (0).
EPIXLXRXEPIX / LXRX
Capitalization79.5M390M20%
EBITDA-27.57M-185.05M15%
Gain YTD-71.667-22.222323%
P/E RatioN/AN/A-
Revenue03.64M-
Total Cash131M310M42%
Total Debt342K101M0%
FUNDAMENTALS RATINGS
EPIX vs LXRX: Fundamental Ratings
EPIX
LXRX
OUTLOOK RATING
1..100
263
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9397
PRICE GROWTH RATING
1..100
9865
P/E GROWTH RATING
1..100
10036
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EPIX's Valuation (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for LXRX (63) in the Biotechnology industry. This means that EPIX’s stock grew somewhat faster than LXRX’s over the last 12 months.

EPIX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as LXRX (100) in the Biotechnology industry. This means that EPIX’s stock grew similarly to LXRX’s over the last 12 months.

EPIX's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as LXRX (97) in the Biotechnology industry. This means that EPIX’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for EPIX (98) in the Pharmaceuticals Major industry. This means that LXRX’s stock grew somewhat faster than EPIX’s over the last 12 months.

LXRX's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for EPIX (100) in the Pharmaceuticals Major industry. This means that LXRX’s stock grew somewhat faster than EPIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EPIXLXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 15 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 15 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 15 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 15 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
Bearish Trend 13 days ago
87%
Bearish Trend 20 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 15 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 15 days ago
87%
View a ticker or compare two or three
Ad is loading...
EPIX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GATCX46.51N/A
N/A
Gabelli Asset C
CADVX19.66-0.05
-0.25%
Calamos Dividend Growth A
PRJBX48.01-0.16
-0.33%
PGIM Jennison Global Opportunities R2
JFCAX38.36-0.17
-0.44%
JHancock Fundamental All Cap Core A
BRSIX12.76-0.22
-1.69%
Bridgeway Ultra-Small Company Market

EPIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, EPIX has been closely correlated with LOGC. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EPIX jumps, then LOGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPIX
1D Price
Change %
EPIX100%
+4.47%
LOGC - EPIX
67%
Closely correlated
-0.94%
LXRX - EPIX
44%
Loosely correlated
-6.30%
PCVX - EPIX
31%
Poorly correlated
-4.05%
MREO - EPIX
27%
Poorly correlated
-4.21%
NKTX - EPIX
27%
Poorly correlated
-10.32%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with EPIX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-6.30%
EPIX - LXRX
45%
Loosely correlated
+4.47%
FRTX - LXRX
41%
Loosely correlated
N/A
ABCL - LXRX
41%
Loosely correlated
-6.35%
BEAM - LXRX
40%
Loosely correlated
-7.94%
SCPH - LXRX
39%
Loosely correlated
-7.09%
More